PYPD
Closed
Polypid
3.53
0.00 (0.00%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 3.53
Day's Range: 3.42 - 3.58
Send
sign up or login to leave a comment!
When Written:
0.43
PolyPid is a clinical-stage biopharmaceutical company based in Israel that specializes in the development of long-acting, local drug delivery solutions to prevent surgical site infections and other complications. The company's proprietary platform technology, called PolyPid™, is designed to provide controlled and sustained release of antibiotics and other therapeutic agents directly at the site of surgical incision or injury, thereby reducing the risk of infection and improving patient outcomes.
PolyPid's lead product candidate, D-PLEX™, is a novel antibiotic drug delivery system designed to prevent surgical site infections in patients undergoing abdominal surgery. D-PLEX™ is composed of a biodegradable polymer matrix that is infused with the antibiotic agent doxycycline, which is released over a period of several weeks to provide sustained protection against bacterial infection.
PolyPid is also developing other product candidates based on its PolyPid™ platform technology, including a local drug delivery system for the treatment of osteomyelitis (a bone infection) and a drug-eluting stent for the treatment of cardiovascular disease.
PolyPid was founded in 2008 and has received funding from a variety of sources, including venture capital firms, government grants, and partnerships with pharmaceutical companies. The company completed its initial public offering (IPO) on the Nasdaq stock exchange in February 2021.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
PolyPid's lead product candidate, D-PLEX™, is a novel antibiotic drug delivery system designed to prevent surgical site infections in patients undergoing abdominal surgery. D-PLEX™ is composed of a biodegradable polymer matrix that is infused with the antibiotic agent doxycycline, which is released over a period of several weeks to provide sustained protection against bacterial infection.
PolyPid is also developing other product candidates based on its PolyPid™ platform technology, including a local drug delivery system for the treatment of osteomyelitis (a bone infection) and a drug-eluting stent for the treatment of cardiovascular disease.
PolyPid was founded in 2008 and has received funding from a variety of sources, including venture capital firms, government grants, and partnerships with pharmaceutical companies. The company completed its initial public offering (IPO) on the Nasdaq stock exchange in February 2021.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








